PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients

被引：3
|
作者：
Contreras, A.
Herrera, S.
Wang, T.
Mayer, I.
Forero, A.
Nanda, R.
Goetz, M.
Chang, J. C.
Pavlick, A. C.
Fuqua, S. A. W.
Gutierrez, C.
Hilsenbeck, S. G.
Li, M. M.
Osborne, C. K.
Schiff, R.
Rimawi, M. F.
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Vanderbilt Univ, Nashville, TN 37235 USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Univ Chicago, Chicago, IL 60637 USA
[5] Mayo Clin, Rochester, MN USA
[6] Methodist Hosp, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2013年 / 73卷
关键词：
D O I：
10.1158/0008-5472.SABCS13-PD1-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD1-2
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Predictive factors of resistance to trastuzumab as neoadjuvant therapy in women with HER2-positive breast cancer
    Jinno, Hiromitsu
    Sato, Tomomi
    Takahashi, Maiko
    Hayashida, Tetsu
    Hirose, Shigemichi
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [42] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    CANCER CONTROL, 2023, 30
  • [43] Mechanisms behind trastuzumab resistance as neoadjuvant therapy in HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    CANCER RESEARCH, 2012, 72
  • [44] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    CANCER CONTROL, 2022, 29
  • [45] Clinicopathological Factors Predicting Pathological Complete Response to Neoadjuvant Anti-HER2 Therapy in HER2-Positive Breast Cancer
    Jung, Youn Joo
    Lee, Seungju
    Kang, Seok Kyeong
    Kim, Jee Yeon
    Choo, Ki Seok
    Nam, Kyung Jin
    Joo, Ji Hyeon
    Kim, Jae Joon
    Kim, Hyun Yul
    ONCOLOGY, 2024,
  • [46] Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial)
    Guarneri, Valentina
    Frassoldati, Antonio
    Piacentini, Federico
    Jovic, Gordana
    Giovannelli, Simona
    Oliva, Cristina
    Conte, PierFranco
    CLINICAL BREAST CANCER, 2008, 8 (02) : 192 - 194
  • [47] Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA-BRCA data
    Chen, Haizhu
    Hu, Xingbin
    Wang, Daquan
    Wang, Ying
    Yu, Yunfang
    Yao, Herui
    TRANSLATIONAL ONCOLOGY, 2023, 37
  • [48] Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients
    Sawaki, Masataka
    Taira, Naruto
    Uemura, Yukari
    Saito, Tsuyoshi
    Baba, Shinichi
    Kobayashi, Kokoro
    Kawashima, Hiroaki
    Tsuneizumi, Michiko
    Sagawa, Noriko
    Bando, Hiroko
    Takahashi, Masato
    Yamaguchi, Miki
    Takashima, Tsutomu
    Nakayama, Takahiro
    Kashiwaba, Masahiro
    Mizuno, Toshiro
    Yamamoto, Yutaka
    Iwata, Hiroji
    Kawahara, Takuya
    Ohashi, Yasuo
    Mukai, Hirofumi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) : 3743 - +
  • [49] Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
    Palmieri, Carlo
    Macpherson, Iain R. J.
    Yan, Kelvin
    Ades, Felipe
    Riddle, Pippa
    Ahmed, Riz
    Owadally, Waheeda
    Stanley, Barbara
    Shah, Deep
    Gojis, Ondrej
    Januszewski, Adam
    Lewanski, Conrad
    Asher, Rebecca
    Lythgoe, Daniel
    de Azambuja, Evandro
    Beresford, Mark
    Howell, Sacha J.
    ONCOTARGET, 2016, 7 (11) : 13209 - 13220
  • [50] An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer
    Sueta, Aiko
    Yamamoto, Yutaka
    Yamamoto-Ibusuki, Mutsuko
    Hayashi, Mitsuhiro
    Takeshita, Takashi
    Yamamoto, Satoko
    Iwase, Hirotaka
    PLOS ONE, 2014, 9 (12):
12345